Method for predicting receptivity to targeted anticancer drug
AssigneeCbsbioscience Co., Ltd
InventorsJin Young PARK, Young Ho Moon, Jung-Hee Kwon
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for predicting sensitivity to treatment with a vascular endothelial growth factor receptor (VEGFR) inhibitor. According to the present invention, effects on the treatment of liver cancer patients with a vascular endothelial growth factor receptor (VEGFR) inhibitor are predicted. Based on the prediction, an effective means and anticancer therapy for treatment of liver cancer are selected, thereby increasing treatment effects and minimizing the side effects of liver cancer treatment.
Claims18
A method for predicting sensitivity to a vascular endothelial growth factor receptor (VEGFR) inhibitor, the method comprising the steps of:
- (a) measuring expression levels of transcription factor 3 (TCF3) in samples isolated from liver cancer patients;
- and
- (b) comparing the expression levels of the transcription factor 3 (TCF3) with a reference level, and selecting samples having a transcription factor 3 (TCF3) expression level equal to or higher than the reference level.
A method for predicting sensitivity to a vascular endothelial growth factor receptor (VEGFR) inhibitor comprising administering an agent for measuring mRNA expression levels of any one or more genes selected from among transcription factor 3 (TCF3), cadherin 1 (CDH1), inhibitor of DNA binding 2, and matrix metallopeptidase 9 (MMP9) to samples isolated from liver cancer patients.
-16. (canceled)
A method for treating liver cancer, comprising the steps of:
- (a) measuring expression levels of transcription factor 3 (TCF3) in samples isolated from liver cancer patients, and measuring expression levels of any one or more selected from among cadherin 1 (CDH1), inhibitor of DNA binding 2, and matrix metallopeptidase 9 (MMP9) in the samples;
- (b) calculating risk scores of the genes in step (a);
- (c) comparing the calculated risk scores with a reference level, and selecting samples having a risk score equal to or higher than the reference level;
- and
- (d) administering a therapeutically effective amount of a vascular endothelial growth factor receptor (VEGFR) inhibitor to a liver cancer patient having a risk score equal to or higher than the reference level.
(canceled)
Dependencies are inferred from the claim text.